Buchumschlag

Safety, pharmacokinetics and efficacy of selumetinib in Chinese adult and paediatric patients with neurofibromatosis type 1 and inoperable plexiform neurofibromas: The primary analysis of a phase 1 open‐label study

Fuente: Wiley Open Access

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	Zhichao Wang, Xin Zhang, Chunyan Li, Yangbo Liu, Xiaoyun Ge, Jiajia Zhao, Xiaojun Yuan, Qingfeng Li
Format:	Artículo Open Access
Veröffentlicht:	Wiley 2024
Schlagworte:	Clinical and Translational Medicine
Online-Zugang:	Acceder al recurso
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge

A phase I, randomized, placebo‐controlled trial to evaluate the pharmacokinetics, safety, and tolerability of nirsevimab in healthy Chinese adults
von: Xiaomeng Mao, et al.
Veröffentlicht: (2024)

Safety, pharmacokinetics, and food effect of sudapyridine (WX‐081), a novel anti‐tuberculosis candidate in healthy Chinese subjects
von: Chengyin Yu, et al.
Veröffentlicht: (2024)

Safety and efficacy of isocitrate dehydrogenase‐1 inhibitor ivosidenib in patients with cholangiocarcinoma
von: Lindsay Wong, et al.
Veröffentlicht: (2026)

A pharmacokinetic study comparing the biosimilar HEC14028 and Dulaglutide (Trulicity®) in healthy Chinese subjects
von: Xianglei Gao, et al.
Veröffentlicht: (2024)

Safety, pharmacokinetics, and pharmacodynamics in healthy Chinese volunteers treated with SC0062, a highly selective endothelin‐A receptor antagonist
von: Yun Liu, et al.
Veröffentlicht: (2024)

Population pharmacokinetics and exposure‐response analyses for efficacy and safety of upadacitinib in patients with axial spondyloarthritis
von: Sumit Bhatnagar, et al.
Veröffentlicht: (2024)

Successful utilization of topical trametinib for neurofibromatosis type I‐associated plexiform neurofibroma
von: Leonid Melnikov, et al.
Veröffentlicht: (2024)

Safety, pharmacokinetics, and pharmacodynamics of nomlabofusp (CTI‐1601) in Friedreich's ataxia
von: Russell Clayton, et al.
Veröffentlicht: (2024)

Effect of SLC22A1 polymorphism on the pharmacokinetics of proguanil in Korean: A semi‐physiologic population pharmacokinetic approach
von: Juyoung Khwarg, et al.
Veröffentlicht: (2024)

Safety, pharmacokinetics, and pharmacodynamics of anti‐IL‐4Rα antibody SHR‐1819 in healthy subjects: A randomized, controlled phase I study
von: Na Li, et al.
Veröffentlicht: (2024)

Population pharmacokinetics of iruplinalkib in healthy volunteers and patients with solid tumors
von: Guihong Yang, et al.
Veröffentlicht: (2024)

Investigation of pharmacokinetic drug interaction between clesacostat and DGAT2 inhibitor ervogastat in healthy adult participants
von: Aarti Sawant‐Basak, et al.
Veröffentlicht: (2024)

Effects of the selective AMPA modulator NBI‐1065845 on the pharmacokinetics of midazolam or ethinyl estradiol–levonorgestrel in healthy adults
von: Swan Lin, et al.
Veröffentlicht: (2024)

HepAssis2 ® bioartificial liver system in treating acute‐on‐chronic liver failure patients: Findings from a phase 1 randomised, open‐label clinical trial
von: Zibiao Zhong, et al.
Veröffentlicht: (2026)

Drug–drug interactions between pemafibrate and statins on pharmacokinetics in healthy male volunteers: Open‐label, randomized, 6‐sequence, 3‐period crossover studies
von: Tomohiro Kamimura, et al.
Veröffentlicht: (2024)

Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of SAR439459, a TGFβ inhibitor, as monotherapy and in combination with cemiplimab in patients with advanced solid tumors: Findings from a phase 1/1b study
von: Joaquina C. Baranda, et al.
Veröffentlicht: (2024)

Pharmacokinetics and Safety of Polaprezinc Granules Oral Administration in Healthy Chinese Volunteers Under Fasting and Fed Conditions
von: Min Xiao, et al.
Veröffentlicht: (2025)

Pharmacokinetics and Safety of Single and Multiple Doses of Molnupiravir in Healthy Male Chinese Adults: An Open‐Label, Fixed Sequence, Phase 1 Study
von: Jixiang Zhu, et al.
Veröffentlicht: (2026)

Correction to “Safety, tolerability, pharmacokinetic/pharmacodynamic characteristics of bersiporocin, a novel prolyl‐tRNA synthetase inhibitor, in healthy subjects”
Veröffentlicht: (2024)

Platelet volume could predict the efficacy of thrombopoietin receptor agonists in the treatment of patients with primary immune thrombocytopenia
von: Bei Xu, et al.
Veröffentlicht: (2025)

Safety, pharmacokinetics, and pharmacodynamics of sofnobrutinib, a novel non‐covalent BTK inhibitor, in healthy subjects: First‐in‐human phase I study
von: Kyoko Miyamoto, et al.
Veröffentlicht: (2024)

Comprehensive multi‐omics analysis of resectable locally advanced gastric cancer: Assessing response to neoadjuvant camrelizumab and chemotherapy in a single‐center, open‐label, single‐arm phase II trial
von: Yuzhou Zhao, et al.
Veröffentlicht: (2024)

Pharmacokinetics and safety of erenumab in pediatric patients with migraine: A phase I, randomized, open‐label, multiple‐dose study
von: Andrew D. Hershey, et al.
Veröffentlicht: (2024)

Safety, pharmacokinetics, and pharmacodynamics of ART‐648, a PDE4 inhibitor in healthy subjects: A randomized, placebo‐controlled phase I study
von: Akira Tanaka, et al.
Veröffentlicht: (2024)

Safety, tolerability, and pharmacokinetics of single‐ and multiple‐ascending doses of olamkicept: Results from randomized, placebo‐controlled, first‐in‐human phase I trials
von: Frank‐Dietrich Wagner, et al.
Veröffentlicht: (2024)

Bortezomib in previously treated phosphatase and tension homology‐deficient patients with advanced intrahepatic cholangiocarcinoma: An open‐label, prospective and single‐centre phase II trial
von: Tian‐mei Zeng, et al.
Veröffentlicht: (2024)

Population pharmacokinetics and CD20 binding dynamics for mosunetuzumab in relapsed/refractory B‐cell non‐Hodgkin lymphoma
von: Brendan Bender, et al.
Veröffentlicht: (2024)

Safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral allosteric TYK2 inhibitor ESK‐001 using a randomized, double‐blind, placebo‐controlled study design
von: Sibel Ucpinar, et al.
Veröffentlicht: (2024)

Mass balance and pharmacokinetic characterization of zavegepant in healthy male subjects
von: Rajinder Bhardwaj, et al.
Veröffentlicht: (2024)

Plasma EBV quantification is associated with the efficacy of immune checkpoint blockade and disease monitoring in patients with primary pulmonary lymphoepithelioma‐like carcinoma
von: Yu‐Min Zhong, et al.
Veröffentlicht: (2024)

Safety, Tolerability, and Pharmacokinetics of SC1011 (Sufenidone), a Novel Antifibrotic Small Molecule, in Phase 1 Studies in Healthy Subjects
von: Yun Liu, et al.
Veröffentlicht: (2025)

Targeting capacity, safety and efficacy of engineered extracellular vesicles delivered by transdermal microneedles to treat plasmacytoma in mice
von: Yulin Cao, et al.
Veröffentlicht: (2025)

Correction to “Clinical pharmacokinetics of atropine oral gel formulation in healthy volunteers”
Veröffentlicht: (2024)

Novel insights on genetics and epigenetics as clinical targets for paediatric astrocytoma
von: Dona A. Johns, et al.
Veröffentlicht: (2024)

Data standards for single‐cell RNA ‐sequencing of paediatric cancer
von: Xiaohan Xu, et al.
Veröffentlicht: (2025)

Data standards for single‐cell RNA‐sequencing of paediatric cancer
Veröffentlicht: (2025)

CRISPR‐driven diagnostics: Molecular mechanisms, clinical efficacy and translational challenges
von: Zilong Wang, et al.
Veröffentlicht: (2025)

LNP‐mediated in vivo base editing corrects Agxt to cure primary hyperoxaluria type 1
von: Dexin Zhang, et al.
Veröffentlicht: (2025)

Modeling the subcutaneous pharmacokinetics of antibodies co‐administered with rHuPH20
von: Ryan P. Nolan, et al.
Veröffentlicht: (2024)

Randomized, double‐blind, phase 1a single‐ascending dose and food effect studies assessing safety and pharmacokinetics of EC5026 in healthy volunteers
von: William K. Schmidt, et al.
Veröffentlicht: (2024)